News

Decorative pattern

Arecor Therapeutics raises £6.4 million via a placing, subscription and retail offer

July 2024

Arecor Therapeutics is an AIM listed biopharmaceutical company transforming patient care by bringing innovative medicines to market.  Through the enhancement of existing medicines using their Arestat™ technology, they are developing a broad portfolio of therapies as part of their proprietary pipeline and through partnerships with leading pharmaceutical and biotech companies.

Their treatments for people living with chronic disease are designed to simplify patient care and improve medication adherence.

Placing, Subscription and Retail Offer

Arecor has successfully raised £6.4 million via the issue of 7,129,615 New Ordinary Shares at 90 pence per New Ordinary Share.

Having helped Arecor with their admission document when they floated on AIM in June 2021, The Perivan shareholder communications team was delighted to work with Panmure Liberum who acted as Nominated Adviser, Global Coordinator, Joint Bookrunner and Joint Broker on the documentation which was successfully produced and posted to qualifying shareholders on 23rd July 2024.

Perivan specialise in producing and publishing financial documents relating to shareholder and investor communications for quoted companies and are a market leader for the production of documentation relating to corporate finance transactions.